Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models

Abstract Objectives Uncertainty around clinical heterogeneity and outcomes for patients with JDM represents a major burden of disease and a challenge for clinical management. We sought to identify novel classes of patients having similar temporal patterns in disease activity and relate them to baseline clinical features. Methods Data were obtained for n = 519 patients, including baseline demographic and clinical features, baseline and follow-up records of physician’s global assessment of disease (PGA), and skin disease activity (modified DAS). Growth mixture models (GMMs) were fitted to identify classes of patients with similar trajectories of these variables. Baseline predictors of class membership were identified using Lasso regression. Results GMM analysis of PGA identified two classes of patients. Patients in class 1 (89%) tended to improve, while patients in class 2 (11%) had more persistent disease. Lasso regression identified abnormal respiration, lipodystrophy and time since diagnosis as baseline predictors of class 2 membership, with estimated odds ratios, controlling for the other two variables, of 1.91 for presence of abnormal respiration, 1.92 for lipodystrophy and 1.32 for time since diagnosis. GMM analysis of modified DAS identified three classes of patients. Patients in classes 1 (16%) and 2 (12%) had higher levels of modified DAS at diagnosis that improved or remained high, respectively. Patients in class 3 (72%) began with lower DAS levels that improved more quickly. Higher proportions of patients in PGA class 2 were in DAS class 2 (19%, compared with 16 and 10%). Conclusion GMM analysis identified novel JDM phenotypes based on longitudinal PGA and modified DAS.

[1]  N. McHugh,et al.  The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity , 2020, Rheumatology.

[2]  J. Stinson,et al.  Being on the juvenile dermatomyositis rollercoaster: a qualitative study , 2019, Pediatric Rheumatology.

[3]  M. Mahler,et al.  Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies , 2019, Front. Immunol..

[4]  I. Sjaastad,et al.  Assessment of Microvascular Abnormalities by Nailfold Capillaroscopy in Juvenile Dermatomyositis After Medium‐ to Long‐Term Followup , 2018, Arthritis care & research.

[5]  T. Southwood,et al.  Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling , 2018, Arthritis & rheumatology.

[6]  I. Sjaastad,et al.  Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement , 2017, The Journal of Rheumatology.

[7]  D. Gladman,et al.  Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients , 2017, Pediatric Rheumatology.

[8]  Richard A Van Dorn,et al.  Visualization of Categorical Longitudinal and Times Series Data. , 2016, Methods report.

[9]  Benoit Liquet,et al.  Estimation of extended mixed models using latent classes and latent processes: the R package lcmm , 2015, 1503.00890.

[10]  I. Sjaastad,et al.  Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. , 2014, Rheumatology.

[11]  T. Jacques,et al.  Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study , 2014, Arthritis Research & Therapy.

[12]  P. Mathiesen,et al.  Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. , 2014, Rheumatology.

[13]  I. Sjaastad,et al.  Increased Levels of Eotaxin and MCP-1 in Juvenile Dermatomyositis Median 16.8 Years after Disease Onset; Associations with Disease Activity, Duration and Organ Damage , 2014, PloS one.

[14]  L. Andersen,et al.  Aerobic fitness after JDM--a long-term follow-up study. , 2013, Rheumatology.

[15]  J. Malley,et al.  The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies , 2013, Medicine.

[16]  P. Mathiesen,et al.  Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study , 2012, Scandinavian journal of rheumatology.

[17]  Yang Yuan,et al.  Multiple Imputation Using SAS Software , 2011 .

[18]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[19]  B. Feldman,et al.  Efficacy of intravenous Ig therapy in juvenile dermatomyositis , 2011, Annals of the rheumatic diseases.

[20]  R. Schneider,et al.  Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. , 2011, Rheumatology.

[21]  L. Wedderburn,et al.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies , 2010, Rheumatology.

[22]  B. Lie,et al.  Long‐term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case–control study , 2010, Arthritis care & research.

[23]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[24]  A. Martini,et al.  Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.

[25]  L. Wedderburn,et al.  Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis , 2009, Arthritis and rheumatism.

[26]  B. Feldman,et al.  Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. , 2008, Arthritis and rheumatism.

[27]  L. Wedderburn,et al.  Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. , 2007, Rheumatology.

[28]  Søren Højsgaard,et al.  The R Package geepack for Generalized Estimating Equations , 2005 .

[29]  B. Feldman,et al.  Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. , 2000, Arthritis and rheumatism.

[30]  G. Celeux,et al.  An entropy criterion for assessing the number of clusters in a mixture model , 1996 .

[31]  B. Bernstein,et al.  Course of treated juvenile dermatomyositis. , 1984, The Journal of pediatrics.

[32]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[33]  Bengt Muthén,et al.  LONGITUDINAL STUDIES OF ACHIEVEMENT GROWTH USING LATENT VARIABLE MODELING , 1998 .

[34]  R. Tibshirani Regression Shrinkage and Selection via the Lasso , 1996 .